Regression discontinuity analysis of Gavi's impact on vaccination rates

Sarah Dykstra, Amanda Glassman, Charles Kenny and Justin Sandefur

Journal of Development Economics, 2019, vol. 140, issue C, 12-25

Abstract: Since 2001, an aid consortium known as Gavi has accounted for over half of vaccines purchased in the 75 eligible countries with an initial GNI below $1,000 per capita. Regression discontinuity estimates suggest most aid for cheap, existing vaccines like hepatitis B and DPT was inframarginal: for instance, hepatitis B doses sufficient to vaccinate roughly 75% of infants raised vaccination rates by single-digit margins. These results are driven by middle-income countries near the eligibility threshold, and do not preclude larger gains for the poorest countries, global externalities via vaccine markets, or impacts on newer vaccines such as pneumococcal or rotavirus for which income eligibility rules were relaxed.

Keywords: Aid; Vaccination; Immunization; Fungibility; Regression discontinuity (search for similar items in EconPapers)
JEL-codes: F35 H51 I15 O11 (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0304387819305309
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:deveco:v:140:y:2019:i:c:p:12-25

DOI: 10.1016/j.jdeveco.2019.04.005

Access Statistics for this article

Journal of Development Economics is currently edited by M. R. Rosenzweig

More articles in Journal of Development Economics from Elsevier
Bibliographic data for series maintained by Catherine Liu ().